@xconomy.com 1 year ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com 1 year ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial